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:   glucagon‐like peptide‐1
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:   International Classification of Diseases
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:   oral hypoglycemic agent

SGLT‐2

:   sodium glucose cotransporter‐2

STAR\*D

:   sequenced treatment alternatives to relieve depression

T2DM

:   type 2 diabetes mellitus

1. INTRODUCTION {#prp2536-sec-0001}
===============

The worldwide prevalence of depression and depressive symptoms has been increasing in recent decades,[1](#prp2536-bib-0001){ref-type="ref"} and the number of patients with depression globally has reached 300 million.[2](#prp2536-bib-0002){ref-type="ref"} Depression accounts for the biggest share of the world\'s burden of disease.[3](#prp2536-bib-0003){ref-type="ref"}

The number of patients with type 2 diabetes mellitus (T2DM) is increasing, and there will be 380 million people with T2DM by 2025.[4](#prp2536-bib-0004){ref-type="ref"}, [5](#prp2536-bib-0005){ref-type="ref"} In order to treat T2DM, the use of oral hypoglycemic agents (OHAs), including metformin, α‐glucosidase inhibitors, sulfonylureas, thiazolidinediones, dipeptidyl peptidase‐4 (DPP‐4) inhibitors, and sodium glucose cotransporter‐2 (SGLT‐2) inhibitors, is recommended.[6](#prp2536-bib-0006){ref-type="ref"}, [7](#prp2536-bib-0007){ref-type="ref"} In particular, metformin (the first choice in T2DM) and incretin‐related drugs such as DPP‐4 inhibitors and glucagon‐like peptide‐1 (GLP‐1) analogs have good glycemic control.[8](#prp2536-bib-0008){ref-type="ref"}, [9](#prp2536-bib-0009){ref-type="ref"}, [10](#prp2536-bib-0010){ref-type="ref"}, [11](#prp2536-bib-0011){ref-type="ref"}

Recently, an association between T2DM and depression has been reported in several studies with a cross‐sectional design.[12](#prp2536-bib-0012){ref-type="ref"}, [13](#prp2536-bib-0013){ref-type="ref"}, [14](#prp2536-bib-0014){ref-type="ref"} The prevalence of depression in patients with T2DM tend to be low in East Asia compared to Europe and the US (China 6.1%; UK 9.3%; US 10.6%; Spain 32.7%). Additionally, in each country, the prevalence of depression in female patients is larger than male patients.[14](#prp2536-bib-0014){ref-type="ref"}, [15](#prp2536-bib-0015){ref-type="ref"}, [16](#prp2536-bib-0016){ref-type="ref"}, [17](#prp2536-bib-0017){ref-type="ref"} In addition, it has been suggested that T2DM is one of the risk factors for depression.[18](#prp2536-bib-0018){ref-type="ref"}, [19](#prp2536-bib-0019){ref-type="ref"} Furthermore, it is known that DM and depression are independent risk factors for dementia.[20](#prp2536-bib-0020){ref-type="ref"}, [21](#prp2536-bib-0021){ref-type="ref"} It is suggested that DM is associated with brain atrophy, particularly hippocampal atrophy in a study using brain MRI.[22](#prp2536-bib-0022){ref-type="ref"} Patients with comorbid diabetes mellitus and depression have increased risk of dementia.[23](#prp2536-bib-0023){ref-type="ref"} Therefore, it is important to prevent the development of depression in patients with T2DM.

It is reported that mouse models of high‐fat diet and T2DM exhibit not only depressive‐like behavior but also insulin resistance in the brain.[24](#prp2536-bib-0024){ref-type="ref"}, [25](#prp2536-bib-0025){ref-type="ref"}, [26](#prp2536-bib-0026){ref-type="ref"}, [27](#prp2536-bib-0027){ref-type="ref"} In mice with brain‐specific knockout of the insulin receptor, brain insulin resistance induces decreased dopamine turnover, leading to anxiety and depressive‐like behaviors.[28](#prp2536-bib-0028){ref-type="ref"} In human, it has been conceived that peripheral insulin resistance metastasizes to the brain.[29](#prp2536-bib-0029){ref-type="ref"} Peripheral insulin resistance causes hyperinsulinemia, which enhances lipolysis. Enhanced lipolysis release proinflammatory cytokine and produce reactive oxygen species (ROS). As a result, neuroinflammation and brain insulin resistance occurs. Thus, improvement of brain insulin resistance may play an important role in the prevention and treatment of depression.[29](#prp2536-bib-0029){ref-type="ref"}, [30](#prp2536-bib-0030){ref-type="ref"}

The risk of depression may be altered depending on the class of OHAs used for T2DM therapy. Hence, the aim of the present study was to characterize the development of depression in T2DM patients being treated with different classes of OHAs.

2. METHODS {#prp2536-sec-0002}
==========

2.1. Data source {#prp2536-sec-0003}
----------------

The present study was a retrospective cohort study using a clinical database, the Nihon University School of Medicine (NUSM) Clinical Data Warehouse (CDW). NUSM CDW is a centralized data repository that integrates separate databases, including patient demographics, diagnosis, and laboratory data, from the hospital information systems at three hospitals affiliated with NUSM; Nihon University Itabashi Hospital ("I"), Nerima Hikarigaoka Hospital ("H"), and Surugadai Nihon University Hospital ("S"). To protect patient privacy, patient identifiers are replaced by anonymous identifiers in all databases of the CDW.

2.2. Study population {#prp2536-sec-0004}
---------------------

Patients aged 20 and older who had been diagnosed with T2DM for at least 30 days were extracted from NUSM CDW (between 2004 and 2018). These patients included patients treated with OHA monotherapy and patients treated with a combination with OHAs, as well as patients with T2DM who had not taken any OHAs (treated with diet and exercise, "non‐use" in Table [1](#prp2536-tbl-0001){ref-type="table"}). DM was diagnosed according to the Committee for the Classification and Diagnosis of Diabetes Mellitus of the Japan Diabetes Society (defined as fasting plasma glucose level ≥126 mg/dL, casual plasma glucose level ≥200 mg/dL, plasma glucose 2 h after 75 g glucose load ≥200 mg/dL, or hemoglobin A~1c~ (HbA~1c~, NGSP) level ≥6.5%).[31](#prp2536-bib-0031){ref-type="ref"}

###### 

Characteristics of T2DM patients with and without depression

  Characteristics                          T2DM patients (n = 40,214)   FDR‐adjusted *P* value   
  ---------------------------------------- ---------------------------- ------------------------ ---------
  Age (years), mean ± SD                   60.48 ± 13.71                60.69 ± 13.36            .5247
  Female, n (%)                            1020 (50.54%)                15 539 (40.64%)          \<.0001
  HbA~1c~ (%), median (IQR)                5.77 (0.79)                  5.97 (1.18)              \<.0001
  Duration of T2DM (years), median (IQR)   3.64 (5.82)                  3.05 (5.82)              \<.0001
  Hospital                                                                                       .0504
  Surugadai                                477                          10 175                    
  Itabashi                                 1192                         22 173                    
  Hikarigaoka                              310                          5887                      
  Medical history, n                                                                             
  Arrhythmia                               1179                         19 713                   \<.0001
  Hyperlipidemia                           1283                         21 554                   \<.0001
  Hypertension                             1244                         21 570                   \<.0001
  Rheumatoid arthritis                     383                          4980                     \<.0001
  Thyroid disease                          1028                         14 405                   \<.0001
  Liver disease                            1285                         20 576                   \<.0001
  Kidney disease                           729                          13 879                   .6278
  Oral hypoglycemic agents, n                                                                    
  Nonuse (diet and exercise)               1756                         29 868                   \<.0001
  Sulfonylureas                            112                          3404                     \<.0001
  α‐glucosidase inhibitors                 82                           2114                     .0096
  DPP‐4 inhibitors                         54                           3731                     \<.0001
  Biguanides                               41                           1905                     \<.0001
  Thiazolidinediones                       29                           1072                     .0005
  Glinides                                 21                           751                      .0054
  SGLT‐2 inhibitors                        1                            378                      \<.0001

Student\'s *t*‐test was performed for differences in age (skewness = −0.63, kurtosis = −0.09 in case group, and skewness = −0.49, kurtosis = −0.08 in control group). Wilcoxon rank‐sum test was performed for differences in HbA~1c~ (skewness = 2.17, kurtosis = 8.29 in case group, and skewness = 1.78, kurtosis = 4.82 in control group) and duration of T2DM (skewness = 1.65, kurtosis = 3.91 in case group, and skewness = 1.79, kurtosis = 4.27 in control group). Chi‐squared test was performed for differences in categorical variables.

Abbreviations: DPP‐4, dipeptidyl peptidase‐4; FDR, false discovery rate; IQR, interquartile range; SD, standard deviation; SGLT‐2, sodium glucose cotransporter‐2; T2DM, type 2 diabetes mellitus.
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The experimental protocol was approved by the Ethics Committee of the NUSM (approved number: 31‐9‐0), and the study was conducted in compliance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects of the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, Japan.

2.3. Neuropsychiatric evaluation {#prp2536-sec-0005}
--------------------------------

In the present study, the presence or absence of development of depression was regarded as the outcome. The diagnosis of depression was made by medical doctors belonging to either of these three hospitals (according to the International Classification of Diseases \[ICD‐10\] code; F320, F328, F329). Patients with T2DM were divided into "case group (depression)" and "control group (non‐depression)" by the presence or absence of depression. Furthermore, to avoid reverse causation bias, patients who had developed T2DM after the onset of depression were excluded.

It is known that the use of antipsychotic drugs such as olanzapine and quetiapine is a risk factor for hyperglycemia.[32](#prp2536-bib-0032){ref-type="ref"}, [33](#prp2536-bib-0033){ref-type="ref"} In addition, Alzheimer\'s disease (ICD‐10 code; G30.0 ‐ G30.9) and vascular dementia (F01.0‐F01.9) are associated with depression.[34](#prp2536-bib-0034){ref-type="ref"}, [35](#prp2536-bib-0035){ref-type="ref"} Therefore, patients who had used these antipsychotic drugs before the onset date of depression, and patients with a history of these types of dementia were excluded from analysis.

2.4. Co‐variables to assess the risk of depression {#prp2536-sec-0006}
--------------------------------------------------

Age, sex, hospital (I, H, and S), duration of T2DM, HbA~1c~, and medical history were considered as potential confounding factors in this study.

The duration of T2DM in patients of the case group was defined as the number of days from the onset date of T2DM to the onset date of depression (Figure [1](#prp2536-fig-0001){ref-type="fig"}A). Furthermore, the duration of T2DM in patients of the control group was defined as the number of days from the onset date of T2DM to the latest date of diagnosis of T2DM. The duration of T2DM was at least 30 days.

![Definition of duration of T2DM (A), glycemic control (B), and use or nonuse of oral hypoglycemic agents (C). T2DM, type 2 diabetes mellitus; HbA~1c~, hemoglobin A~1c~; OHA, oral hypoglycemic agent](PRP2-7-e00536-g001){#prp2536-fig-0001}

As the degree of glycemic control is associated with symptoms of depression as well as some type 2 diabetes‐related complications,[36](#prp2536-bib-0036){ref-type="ref"}, [37](#prp2536-bib-0037){ref-type="ref"} glycemic control may be a potential risk factor for the development of depression. Therefore, mean value of HbA~1c~ measured at least two times before the onset date of depression was calculated as an index of glycemic control (Figure [1](#prp2536-fig-0001){ref-type="fig"}B).

Medical history included information on arrhythmia (ICD‐10 code; I42‐I50), hyperlipidemia (E78.0‐E78.5), hypertension (I10), rheumatoid arthritis (M05, M06, and M08), thyroid disease (E00‐E07), liver disease (K70‐K77), and kidney disease (N00‐N19) diagnosed before the onset date of depression.

2.5. Criteria for use or nonuse of OHAs {#prp2536-sec-0007}
---------------------------------------

In the present study, sulfonylureas, α‐glucosidase inhibitors, biguanides, thiazolidinediones, glinides, DPP‐4 inhibitors, and SGLT‐2 inhibitors were assessed. In order to assess these OHAs, which are used chronically, OHAs used on 80% or more of days within the duration of T2DM were included in statistical analysis. In addition, OHAs that had been used continuously for at least 30 days before the onset date of depression were also included (Figure [1](#prp2536-fig-0001){ref-type="fig"}C).

2.6. Statistical analysis {#prp2536-sec-0008}
-------------------------

To compare differences in patient background between the case group and the control group, two‐tailed Student\'s *t*‐test or Wilcoxon rank‐sum test was performed for continuous data including age, duration of T2DM, and HbA~1c~. Chi‐squared test was performed for differences in categorical data including sex, hospital, medical history, and use of OHAs. P values were adjusted by false discovery rate (FDR) due to multiple comparisons.

The risk of depression with the different classes of OHAs was assessed by multiple logistic regression analysis; the presence or absence of depression was the dependent variable, the use or nonuse of OHAs was the independent variable, and covariables such as age, sex, HbA~1c~, duration of T2DM, hospital, and medical history were adjusted.

The level of significance was set to.05 for all statistical analyses. All statistical analyses were conducted with SAS software version 9.4 (SAS Institute Inc, Cary).

3. RESULTS {#prp2536-sec-0009}
==========

Figure [2](#prp2536-fig-0002){ref-type="fig"} contains a flowchart depicting patient extractions from NUSM CDW. A total of 41 579 adult patients with T2DM were extracted from NUSM CDW. Of these patients, 1365 were excluded because of use of an antipsychotic drug or the development of dementia. Among the remaining 40 214 patients, 1979 \[female: 1020 (50.54%)\] who had developed depression were assigned to the case group, and 38 235 patients \[female: 15 539 (40.64%)\] who had not developed depression were assigned to the control group.

![A flowchart of patient extractions from NUSM CDW](PRP2-7-e00536-g002){#prp2536-fig-0002}

Characteristics of patients with T2DM are shown in Table [1](#prp2536-tbl-0001){ref-type="table"}. There was no significant difference in age between the case group (60.48 ± 13.71 years, mean ± standard deviation) and the control group (60.69 ± 13.36 years). On the other hand, sex, HbA~1c~, and duration of T2DM were significantly different between the two groups (*P* \< .0001, respectively). The proportion of T2DM patients who developed depression showed no significant difference among the three hospitals (*P* = .0504). With regard to history of seven medical conditions, only kidney disease showed no significant difference between the two groups (*P* = .6278). However, statistical significance of the other six medical conditions (arrhythmia, hyperlipidemia, hypertension, rheumatoid arthritis, thyroid disease, and liver disease) was detected (*P* \< .0001, respectively).

Characteristics of patients with T2DM related to the risk of depression are shown in Table [2](#prp2536-tbl-0002){ref-type="table"}. Age (adjusted odds ratio \[AOR\] for 10 years: 1.03; 95% confidence interval \[CI\]: 0.99‐1.07; *P* = .1211) [38](#prp2536-bib-0038){ref-type="ref"} and duration of T2DM (AOR for 1 year: 1.00; 95% CI: 0.99‐1.01; *P* = .4089) [39](#prp2536-bib-0039){ref-type="ref"} were not associated with the development of depression. However, the risk of depression in female patients with T2DM was significantly higher than that in male patients (AOR: 1.39; 95% CI: 1.26‐1.53; *P* \< .0001). In addition, HbA~1c~ level was significantly associated with the development of depression (AOR for 1.0%: 1.18; 95% CI: 1.11‐1.26; *P* \< .0001). There was no association between hospitals and the risk of depression. Regarding medical history, arrhythmia (AOR: 1.17; 95% CI: 1.06‐1.30; *P* \< .01), hyperlipidemia (AOR: 1.23; 95% CI: 1.12‐1.36; *P* \< .0001), hypertension (AOR: 1.34; 95% CI: 1.21‐1.49; *P* \< .0001), rheumatoid arthritis (AOR: 1.22; 95% CI: 1.08‐1.37; *P* \< .01), thyroid disease (AOR: 1.37; 95% CI: 1.24‐1.51; *P* \< .0001), and liver disease (AOR: 1.34; 95% CI: 1.21‐1.48; *P* \< .0001) were each significantly associated with the onset of depression. However, there was no association between kidney disease and depression (AOR: 0.97; 95% CI: 0.88‐1.08; *P* = .6045).

###### 

Characteristics of patients with T2DM related to the risk of depression

  Characteristics                          Logistic regression coefficient   Adjusted   *P* value   
  ---------------------------------------- --------------------------------- ---------- ----------- ---------
  Age, 10 years                            .0282                             1.03       0.99‐1.07   .1211
  Female                                   .3286                             1.39       1.26‐1.53   \<.0001
  HbA~1c~, 1.0%                            .1678                             1.18       1.11‐1.26   \<.0001
  Duration of T2DM, 1 year                 −.0044                            1.00       0.99‐1.01   .4089
  Hospital (*vs* Surugadai)                                                                         
  Itabashi                                 −.1071                            0.91       0.82‐1.02   .1036
  Hikarigaoka                              −.0920                            0.90       0.77‐1.04   .1597
  Medical history                                                                                   
  Arrhythmia                               .1601                             1.17       1.06‐1.30   .0022
  Hyperlipidemia                           .2091                             1.23       1.12‐1.36   \<.0001
  Hypertension                             .2938                             1.34       1.21‐1.49   \<.0001
  Rheumatoid arthritis                     .1960                             1.22       1.08‐1.37   .0014
  Thyroid disease                          .3159                             1.37       1.24‐1.51   \<.0001
  Liver disease                            .2912                             1.34       1.21‐1.48   \<.0001
  Kidney disease                           −.0263                            0.97       0.88‐1.08   .6045
  Oral hypoglycemic agents (*vs* nonuse)                                                            
  Sulfonylureas                            .0386                             1.04       0.83‐1.30   .7333
  α‐glucosidase inhibitors                 .0466                             1.05       0.82‐1.34   .7081
  DPP‐4 inhibitors                         −1.1572                           0.31       0.24‐0.42   \<.0001
  Biguanides                               −.3160                            0.73       0.52‐1.02   .0621
  Thiazolidinediones                       −.2847                            0.75       0.51‐1.10   .1454
  Glinides                                 −.2932                            0.75       0.48‐1.17   .1974
  SGLT‐2 inhibitors                        −2.4260                           0.09       0.01‐0.63   .0153

Abbreviations: CI, confidence interval; DPP‐4, dipeptidyl peptidase‐4; SGLT‐2, sodium glucose cotransporter‐2; T2DM, type 2 diabetes mellitus.
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After adjustment for patients' characteristics including age, sex, HbA~1c~, duration of T2DM, hospital, and medical history, the use of DPP‐4 inhibitors was significantly associated with the risk of depression compared to nonuse of DPP‐4 inhibitors (AOR: 0.31; 95% CI: 0.24‐0.42; *P* \< .0001). SGLT‐2 inhibitors also significantly decreased the risk of depression (AOR: 0.09; 95% CI: 0.01‐0.63; *P* = .0153), but the number of T2DM patients with depression who had taken SGLT‐2 inhibitors was very small (n = 1 in Table [1](#prp2536-tbl-0001){ref-type="table"}). The use of biguanides tended to decrease the risk of depression (AOR: 0.73; 95% CI: 0.52‐1.02; *P* = .0621). There was no association between the use of the other OHAs (sulfonylureas, α‐glucosidase inhibitors, thiazolidinediones, and glinides) and the risk of depression (*P* \> .05, respectively).

4. DISCUSSION {#prp2536-sec-0010}
=============

As a result of this study, it is suggested that several characteristics including sex, high HbA~1c~, and medical history increase the risk of depression. Several reports that women have higher rates of depression compared with men regardless of the presence or absence of diabetes mellitus have been published.[40](#prp2536-bib-0040){ref-type="ref"}, [41](#prp2536-bib-0041){ref-type="ref"}, [42](#prp2536-bib-0042){ref-type="ref"} This finding that sex is a risk factor for depression has been supported by previous reports. Regarding glycemic control, it was suggested that high HbA~1c~ increases the risk of depression in the present study. Ravona‐Springer, et al have reported an association between HbA~1c~ variability and symptoms of depression.[37](#prp2536-bib-0037){ref-type="ref"} It is known that intensive glycemic control decreases the risk of diabetic complications including retinopathy, nephropathy, and neuropathy.[43](#prp2536-bib-0043){ref-type="ref"}, [44](#prp2536-bib-0044){ref-type="ref"} Therefore, glycemic control may play an important role in reducing the development of depression as well as preventing diabetic complications.

It is known that exercise in patients with T2DM not only improves peripheral insulin resistance but also lowers HbA~1c~ values.[45](#prp2536-bib-0045){ref-type="ref"}, [46](#prp2536-bib-0046){ref-type="ref"} In addition, exercise improves brain structural abnormalities and is associated with prevention of depression in depressed patients.[47](#prp2536-bib-0047){ref-type="ref"}, [48](#prp2536-bib-0048){ref-type="ref"} However, use of DPP‐4 inhibitors provides a lower risk of depression compared to nonuse of DPP‐4 inhibitors. Thus, the use of DPP‐4 inhibitors are more suitable than nonuse in terms of the risk of depression.

Brain insulin resistance is associated with depression.[29](#prp2536-bib-0029){ref-type="ref"}, [30](#prp2536-bib-0030){ref-type="ref"} It is known that thiazolidinediones (pioglitazone and rosiglitazone) and metformin reduce insulin resistance and improve insulin sensitivity.[6](#prp2536-bib-0006){ref-type="ref"}, [49](#prp2536-bib-0049){ref-type="ref"} In addition, these drugs penetrate the blood‐brain barrier (BBB).[50](#prp2536-bib-0050){ref-type="ref"}, [51](#prp2536-bib-0051){ref-type="ref"}, [52](#prp2536-bib-0052){ref-type="ref"} For this reason, these drugs may improve insulin resistance in brain tissue as well as peripheral tissue.[53](#prp2536-bib-0053){ref-type="ref"} However, the use of these drugs did not reduce the risk of depression in the present study. Therefore, it is suggested that improvement of insulin resistance in the brain does not decrease the risk of depression.

It was suggested that the use of DPP‐4 inhibitors and SGLT‐2 inhibitors decreases the risk of depression. However, it is unclear whether SGLT‐2 inhibitors decrease the risk of depression because the number of T2DM patients with depression who had taken SGLT‐2 inhibitors in this study was very small. DPP‐4 is responsible for the degradation of incretins such as glucagon‐like peptide‐1 (GLP‐1) and gastric inhibitory polypeptide. It has been suggested that GLP‐1 and its receptor agonists pass through the BBB.[54](#prp2536-bib-0054){ref-type="ref"}, [55](#prp2536-bib-0055){ref-type="ref"} GLP‐1 receptors are expressed in various regions of the brain including the hippocampus, neocortex, and cerebellum.[56](#prp2536-bib-0056){ref-type="ref"} Activation of the GLP‐1 receptor in the brain promotes neuroprotection in neurodegenerative disorders such as Alzheimer\'s disease, Parkinson\'s disease, and multiple sclerosis.[57](#prp2536-bib-0057){ref-type="ref"}, [58](#prp2536-bib-0058){ref-type="ref"}, [59](#prp2536-bib-0059){ref-type="ref"} An association between depression and neurodegeneration has been reported in several studies.[60](#prp2536-bib-0060){ref-type="ref"}, [61](#prp2536-bib-0061){ref-type="ref"} In addition, chronic activation of the GLP‐1 receptor in the brain of rats ameliorates depression‐like behavior.[62](#prp2536-bib-0062){ref-type="ref"} In this study, patients with T2DM had taken DPP‐4 inhibitors for at least 30 days. Therefore, chronic activation of GLP‐1 receptors in the brain may play a potential role in decreasing the risk of depression.

4.1. Limitations {#prp2536-sec-0011}
----------------

The present study has some limitations. Firstly, some of female patients analyzed in this study have reached menopause. It is known that women who reached menopause have the second peak of schizophrenia.[63](#prp2536-bib-0063){ref-type="ref"} Therefore, menopause might have an effect on the risk of depression in female patients with T2DM.

Secondly, the number of patients who developed depression after the onset of T2DM was small irrespective of the class of OHAs. Especially, the use of SGLT‐2 inhibitors significantly decreased the risk of depression, but the number of patients using SGLT‐2 inhibitors was very small. Therefore, the risk of depression has not been assessed accurately in this study. GLP‐1 receptor agonists penetrate the BBB and activate GLP‐1 receptors in the brain.[54](#prp2536-bib-0054){ref-type="ref"}, [64](#prp2536-bib-0064){ref-type="ref"} However, no T2DM patients developed depression among those using a GLP‐1 receptor agonist in the present study. Thus, the effects of GLP‐1 receptor agonists on the risk of depression remain unclear.

Secondly, the present study was a retrospective, nonrandomized study with potential for selection bias and confounding factors. This study controlled potential confounding factors that were available and measurable, but failed to adjust for nonobserved confounding factors. Therefore, the findings obtained in this study should be verified through randomized cohort studies.
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